Unite Against Scleroderma 2012 PDF Print E-mail
Monday, 19 March 2012 21:13

For our second year running, the Scleroderma Care Foundation will be hosting its “Unite Against Scleroderma” Awareness Walk around the Queen’s Park Savannah, Port of Spain. Scheduled to start from 3:00pm, the Walk would be held on Sunday May 6th 2012 and cover one full lap.

The Walk ultimately aims to raise the profile of Scleroderma in the public consciousness - aligned with our ongoing mission to assist Scleroderma patients, their families, and respective communities through mutual social and financial support, educational initiatives, the stimulation of research, and bringing forth a greater awareness of Scleroderma.

We would also be aiming to highlight many of the challenges and needs of those who struggle to cope with Scleroderma daily, and that of the Foundation itself in seeking to secure wider support for its own initiatives and efforts to serve Scleroderma patients.

At the Walk’s end, all participants would be treated to light refreshments, a brief presentation from the Foundation’s President and co-founder Adelwyn Holder, other guest speakers, and performances by specially invited musical guests – all to be later announced.

As we are aware, Scleroderma is a rare, autoimmune, connective tissue disease characterized by the overproduction of collagen, which results in the thickening and hardening of the underlying connective tissues which support the skin, blood vessels, muscles, and internal organs such as the heart, lungs, and kidneys.

Scleroderma can limit a patient’s range of motion and ability to perform simple daily tasks due to fatigue, and the pain, swelling, and inflammation of the joints. With organ involvement, life can become particularly more challenging and life-threatening.

We would really like to encourage each of you to come out - bring your family, children, and friends - and walk with us on May 6th. T-shirts, Scleroderma silicone bands, and pins would also be on sale. All registered participants receive a participatory package inclusive of a branded event t-shirt.

Registration begins April 1st 2012, but you can download and fill out the registration forms from today. Registration costs for adults are $100 and children (under 12) $50. For more information, please do call us at 756-3930 or 685-3213 or email us This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

See below, some of the photos from last year’s Walk, and join us on Facebook to continue the discussion and get further updates, as we near the day :)


To view the rest of the photos, visit our gallery here.

 
More articles :

» ArGentis Seeks More Funding After Obtaining Patent for ARG201 Therapy

ArGentis Pharmaceuticals LLC has received a patent for its scleroderma therapy while finalizing plans for a Phase IIb trial for the treatment known as ARG201.The patent comes nearly two years after it was developed by University of Tennessee Health...

» Survival In Pulmonary Hypertension

Stephen C. Mathai, Laura K. Hummers, Hunter C. Champion, Fredrick M. Wigley, Ari Zaiman, Paul M. Hassoun, and Reda E. GirgisARTHRITIS & RHEUMATISMVol. 60, No. 2, February 2009, pp 569–577 DOI 10.1002/art.24267 © 2009, American College of...

» TLR4 Protein Implicated In The Fibrosis Associated With Scleroderma

An international multi-disciplinary research team led by scientists has uncovered a new role for the protein toll-like receptor 4 (TLR4) in the development of tissue fibrosis, or scarring.Recently reported in the , this finding has implications for...

» Survival in Pulmonary Hypertension Associated With the Scleroderma Spectrum of Diseases

Stephen C. Mathai, Laura K. Hummers, Hunter C. Champion, Fredrick M. Wigley, Ari Zaiman, Paul M. Hassoun, and Reda E. GirgisObjective. Pulmonary hypertension (PH) is an important cause of mortality in systemic sclerosis (SSc), where it can be...

» Scleroderma Foundation Medical Advisory Board Offers Consensus On Gleevec

® (imatinib mesylate, Novartis) is approved in the United States for the treatment of certain forms leukemias and solid tumors. The recent discovery that Gleevec® inhibits important cellular enzymes that control fibrosis led to studies to evaluate...

» Autoimmune Diseases May Increase Cancer Risk

A new study reveals that patients with certain autoimmune diseases are more likely to develop cancer. The new information could help doctors diagnose cancer at a much earlier stage.Two years ago, 67- year- old Dorothy Adams noticed a thickening and...